



21 December 2020

Creso and Adler achieve regulatory approval for anibidiol® in Uruguay

Secures first purchase order for animal health products in LATAM

- **anibidiol® becomes the first approved CBD hemp-based complementary feed for pets in Latin America**
- **Approval allows Creso Pharma to significantly increase footprint in the region**
- **Creso Pharma's representative Medara now able to service several large markets through its commercial partner Adler Laboratorios Uruguay, including Uruguay, Paraguay, Bolivia and Argentina**
- **First purchase order for anibidiol® 8 expected to be delivered in Q1 2021 - underpins Company's growing revenue profile**
- **Additional purchase orders expected shortly in line with Latin America growth strategy**

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to advise it has secured regulatory approval from the Ministry of Agriculture and Animal Feed in Uruguay (Ministerio de Ganadaria, Agricultura y Pesca) through its commercial partner Adler Laboratories, Uruguay for its line of animal health products, anibidiol®. The company expects first purchase order for anibidiol® 8 to be delivered in Q1 2021. This underpins the Company's growing revenue profile in the LATAM region.

anibidiol® is now the first CBD hemp-based complementary feed approved for pets in Latin America which represents a ground breaking milestone from a regulatory and business perspective.

The approval represents a key strategic milestone, which broadens the Company's global footprint. The Latin American market provides a large opportunity for Creso Pharma and unlocks potential access to over 24 million pets across Uruguay, Argentina, Paraguay and Bolivia and further LATAM countries.

Creso Pharma expects to deliver the first purchase order for anibidiol®, from Laboratorios Adler, Uruguay via its representative Medara in Buenos Aires, Argentina in Q1 2021. The purchase order is for 175'000 anibidiol® 8 sachets in 3,300 boxes and valued at A\$89,000 (CHF 60,000). Further purchase orders for other anibidiol®line products are expected in Q1 2021.

The first purchase order in Uruguay follows other recent POs secured for anibidiol® in the EU (see ASX announcement on 2 December 2020), with this latest PO providing further confirmation of the successful take-up of anibidiol® in new and existing markets. The Company anticipates additional purchase orders to materialise in the coming months.



anibidiol@ 2.5

anibidiol @ 8



anibidiol@oil 500



anibidiol@ EQUI

Management Commentary

Jorge Wernli, Creso Commercial Director said: “The approval of anibidiol@ as the first CBD hemp complementary feed in Uruguay, with a simultaneous purchase order is a major achievement for Creso Pharma.

“The Company’s entry into the Latin American market more broadly represents a major strategic development and significant growth opportunity, with potential access to millions of pets across several Latin American countries.”

“We look forward to working with our established, in country representatives to target rapid expansion across the region. We anticipate a number of follow up purchase orders will materialise in the coming months, as we reapidly scale up in Latin America.”

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Creso Board



For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Laboratorios Adler

With years of experience in the veterinary field, Adler Laboratories is proud to be recognized as a leading manufacturer.

Laboratorios Adler is a Uruguayan company founded in 1980 by a multidisciplinary team of professionals in the areas of Veterinary Medicine, Chemical Engineering and Pharmacy, highly recognized in their respective areas for their dedication to study and research.

We are a dynamic company that manufactures, markets and distributes medicines for veterinary use that contribute to improving the animal health of our herd and provide quality solutions for rural producers.

About Medara

Medara is Creso Pharma's commercial representative for LATAM countries. Medara is based in Buenos Aires, Argentina and works with commercial partners with strong presence in a number of LATAM countries.

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties



surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.